哌罗匹隆治疗精神分裂症临床疗效及安全性观察

Clinical Efficacy and Safety Observation of Perospirone in the Treatment of Schizophrenia

目的浅析哌罗匹隆治疗精神分裂症的疗效和安全性。方法采取前瞻性研究,时间为2021年1月至2022年12月,样本量80例,均为本院收治的首发阴性症状精神分裂症患者;随机数字表法分组,其中一组接受常规利培酮治疗,为对照组(n=40),另一组接受哌罗匹隆治疗,为观察组(n=40);比较两组疗效、阳性和阴性症状量表(PANSS)中阴性症状得分、血清泌乳素(PRL)水平、生活质量综合评定问卷(GQOLI-74)评分和不良反应差异。结果(1)观察组治疗总有效率95.00%,对照组治疗总有效率90.00%,两组比较,差异无统计学意义(P>0.05)。(2)两组用药前、用药1个月后及用药2个月后的PANSS评分比较,差异均无统计学意义(P>0.05)。(3)两组用药前的PRL水平和GQOLI-74评分比较,差异均无统计学意义(P>0.05);用药1个月后及用药2个月后,观察组PRL水平较之对照组同期水平更低,观察组GQOLI-74评分较之对照组同期评分更高,差异有统计学意义(P<0.05)。(3)两组体重增加发生率、女性月经紊乱发生率、静坐不能发生率比较,差异均无统计学意义(P>0.05)。结论哌罗匹隆治疗精神分裂症的疗效确切,有助于改善患者的疾病症状,帮助患者重建良好的生活质量,且长期用药不会对患者的PRL水平造成显著影响;不良反应方面可能优于利培酮,但仍需加大样本量追加观察。

Objective To analyze the efficacy and safety of Perospirone in the treatment of schizophrenia.Methods In the prospective study,80 patients with first-episode negative symptoms of schizophrenia treated from January 2021 to December 2022 in our hospital were selected.According to the random number table,patients were assigned to control group(n=40,Risperidone)and observation group(n=40,Perospirone).negative symptom scores,serum prolactin(PRL)level,quality of life comprehensive assessment questionnaire(GQOL I-74)scores and adverse effects were compared in the efficacy,positive and negative symptom scales(PANSS).Results(1)Overall response rate in the observation group 95.00%,and the control group total treatment response rate 90.00%,comparing the two groups,there was no statistically significant difference(P>0.05).(2)Two groups before the medication,1 month after medication and 2 months after medication PANSS for score comparison,no difference was statistically significant(P>0.05).(3)Two groups before medication neither PRL level nor GQOL I-74 score were significant(P>0.05);after 1 month and 2 months,PRL levels were lower in the observation group than in the control group,and the GQOLI-74 score was higher in the observation group,statistically significant(P<0.05).(3)Two groups the incidence of weight gain,incidence of menstrual disorders in women,and incidence of sedentary inability in comparison,there was no statistically significant difference(P>0.05).Conclusion The efficacy of piperopillone in schizophrenia helps to improve the disease symptoms and help patients to rebuild a good quality of life,and long-term medication will not significantly affect the PRL level;adverse effects may be better than risperidone,but the sample size should be increased.